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bClinical Nursing, Ehime University Graduate School of Medicine, Shitsukawa, Toon-City, Ehime 791-0295, JapanThe author regrets that some of the reference citations in the original publication of this article were incorrect.
On Page 6, there is an incorrect citation of Ref. [59]within the caption of Fig. 5. Caption should read: ‘‘Fig. 5. Kaplan–Meier survival curve
for all cause cardiac mortality in disopyramide-treated and non-disopyramide-treated patients with HOCM [60].’’
On Page 9, incorrect citations of Refs. [32,33]within the caption of Table 1. Caption should read: ‘‘Table 1 Effects of beta-blocker, calcium
antagonist, disopyramide, and cibenzoline on LV pressure gradient, LV diastolic dysfunction, LV hypertrophy, and end-stage heart failure,
and side effects of each drug [40,41].’’
The authors would like to apologize for any inconvenience this may have caused to the readers of the journal.DOI of original article: http://dx.doi.org/10.1016/j.jjcc.2014.02.022
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